Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's disease
Biotech
BMS pays Leqembi originator $100M for Alzheimer's prospects
Bristol Myers has turned to the source of Leqembi to push into Alzheimer’s, paying BioArctic $100 million upfront for two preclinical antibodies.
Nick Paul Taylor
Dec 19, 2024 5:23am
Cognition's phase 2 SHIMMER results allow dementia drug to shine
Dec 18, 2024 7:00am
Vivoryon's Alzheimer's asset suffers 2nd phase 2 fail
Dec 9, 2024 7:10am
Alector lays off 17% of staff after ph. 2 Alzheimer's drug fail
Nov 26, 2024 4:50am
Cassava flunks phase 3 Alzheimer's test, stops 2nd trial
Nov 25, 2024 8:45am
Misconduct and the future of neurodegenerative disease research
Nov 15, 2024 9:06am
